Impact of COX2 genotype, ER status and body constitution on risk of early events in different treatment groups of breast cancer patients

International Journal of Cancer

Volumn 135, Issue 8, 2014, Pages 1898-1910

  Markkula, Andrea ^a   Simonsson, Maria ^a   Rosendahl, Ann H ^a   Gaber, Alexander ^a   Ingvar, Christian ^a   Rose, Carsten ^a   Jernström, Helena ^a  

^a LUND UNIVERSITY   (Sweden)

Author keywords

body constitution; breast cancer; COX2; estrogen receptor; treatment response

Indexed keywords

ANTINEOPLASTIC AGENT; CYCLOOXYGENASE 2; ESTROGEN RECEPTOR;

ADULT; AGED; ALLELE; ARTICLE; BODY CONSTITUTION; BREAST CANCER; BREAST SURGERY; CANCER PROGNOSIS; CANCER SURVIVAL; CYCLOOXYGENASE 2 GENE; DISEASE FREE SURVIVAL; EARLY CANCER; FEMALE; FOLLOW UP; GENE EXPRESSION; GENE FREQUENCY; GENETIC ASSOCIATION; GENOTYPE; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; PATIENT IDENTIFICATION; PRIORITY JOURNAL; RISK ASSESSMENT; SINGLE NUCLEOTIDE POLYMORPHISM; SWEDEN; TREATMENT RESPONSE; VERY ELDERLY;

BODY CONSTITUTION; BREAST CANCER; COX2; ESTROGEN RECEPTOR; TREATMENT RESPONSE;

ADULT; AGED; AGED, 80 AND OVER; BREAST NEOPLASMS; CYCLOOXYGENASE 2; DISEASE-FREE SURVIVAL; FEMALE; GENE EXPRESSION; GENE FREQUENCY; GENETIC ASSOCIATION STUDIES; HUMANS; KAPLAN-MEIER ESTIMATE; MAMMARY GLANDS, HUMAN; MIDDLE AGED; ORGAN SIZE; POLYMORPHISM, SINGLE NUCLEOTIDE; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; RECEPTORS, ESTROGEN; RISK FACTORS; TREATMENT OUTCOME;

EID: 84905756990     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.28831     Document Type: Article

References (50)

1. Youlden DR, Cramb SM, Dunn NA, et al. The descriptive epidemiology of female breast cancer: an international comparison of screening, incidence, survival and mortality. Cancer Epidemiol 2012; 36: 237-48.
2. Socialstyrelsen. Cancer i siffror 2013. [The National Board of Health and Welfare. Information about cancer incidence in Sweden 2013.] Availible from: www.socialstyrelsen.se/Lists/Artikelkatalog/Attachments/19108/2013-6-5.pdf.
3. Gonzalez-Angulo AM, Morales-Vasquez F, Hortobagyi GN,. Overview of resistance to systemic therapy in patients with breast cancer. Adv Exp Med Biol 2007; 608: 1-22.
4. Baumgarten SC, Frasor J,. Minireview: Inflammation: an instigator of more aggressive estrogen receptor (ER) positive breast cancers. Mol Endocrinol 2012; 26: 360-71.
5. Brueggemeier RW, Quinn AL, Parrett ML, et al. Correlation of aromatase and cyclooxygenase gene expression in human breast cancer specimens. Cancer Lett 1999; 140: 27-35.
6. Menter DG, Schilsky RL, DuBois RN,. Cyclooxygenase-2 and cancer treatment: understanding the risk should be worth the reward. Clin Cancer Res 2010; 16: 1384-90.
7. Gupta RA, Dubois RN,. Colorectal cancer prevention and treatment by inhibition of cyclooxygenase-2. Nat Rev Cancer 2001; 1: 11-21.
8. Howe LR, Subbaramaiah K, Brown AM, et al. Cyclooxygenase-2: a target for the prevention and treatment of breast cancer. Endocr Relat Cancer 2001; 8: 97-114.
9. Howe LR,. Inflammation and breast cancer. Cyclooxygenase/prostaglandin signaling and breast cancer. Breast Cancer Res 2007; 9: 210.
10. van Nes JG, de Kruijf EM, Faratian D, et al. COX2 expression in prognosis and in prediction to endocrine therapy in early breast cancer patients. Breast Cancer Res Treat 2011; 125: 671-85.
11. Witton CJ, Hawe SJ, Cooke TG, et al. Cyclooxygenase 2 (COX2) expression is associated with poor outcome in ER-negative, but not ER-positive, breast cancer. Histopathology 2004; 45: 47-54.
12. Ferrandina G, Lauriola L, Zannoni GF, et al. Increased cyclooxygenase-2 (COX-2) expression is associated with chemotherapy resistance and outcome in ovarian cancer patients. Ann Oncol 2002; 13: 1205-11.
13. Holmes MD, Chen WY,. Hiding in plain view: the potential for commonly used drugs to reduce breast cancer mortality. Breast Cancer Res 2012; 14: 216.
14. Subbaramaiah K, Morris PG, Zhou XK, et al. Increased levels of COX-2 and prostaglandin E2 contribute to elevated aromatase expression in inflamed breast tissue of obese women. Cancer Discov 2012; 2: 356-65.
15. Glynn SA, Prueitt RL, Ridnour LA, et al. COX-2 activation is associated with Akt phosphorylation and poor survival in ER-negative, HER2-positive breast cancer. BMC Cancer 2010; 10: 626.
16. Milano A, Dal Lago L, Sotiriou C, et al. What clinicians need to know about antioestrogen resistance in breast cancer therapy. Eur J Cancer 2006; 42: 2692-705.
17. Morris PG, Hudis CA, Giri D, et al. Inflammation and increased aromatase expression occur in the breast tissue of obese women with breast cancer. Cancer Prev Res (Phila) 2011; 4: 1021-9.
18. Alonzo-Proulx O, Jong RA, Yaffe MJ,. Volumetric breast density characteristics as determined from digital mammograms. Phys Med Biol 2012; 57: 7443-57.
19. Stuedal A, Ma H, Bernstein L, et al. Does breast size modify the association between mammographic density and breast cancer risk? Cancer Epidemiol Biomarkers Prev 2008; 17: 621-7.
20. Denis GV, Obin MS,. 'Metabolically healthy obesity': origins and implications. Mol Aspect Med 2013; 34: 59-70.
21. Festa-Vasconcellos JS, Piranda DN, Amaral LM, et al. Polymorphisms in cycloxygenase-2 gene and breast cancer prognosis: association between PTGS2 haplotypes and histopathological features. Breast Cancer Res Treat 2012; 132: 251-8.
22. Barry EL, Sansbury LB, Grau MV, et al. Cyclooxygenase-2 polymorphisms, aspirin treatment, and risk for colorectal adenoma recurrence-data from a randomized clinical trial. Cancer Epidemiol Biomarkers Prev 2009; 18: 2726-33.
23. Pereira C, Medeiros RM, Dinis-Ribeiro MJ,. Cyclooxygenase polymorphisms in gastric and colorectal carcinogenesis: are conclusive results available? Eur J Gastroenterol Hepatol 2009; 21: 76-91.
24. Hussain SK, Mu LN, Cai L, et al. Genetic variation in immune regulation and DNA repair pathways and stomach cancer in China. Cancer Epidemiol Biomarkers Prev 2009; 18: 2304-9.
25. Siezen CL, van Leeuwen AI, Kram NR, et al. Colorectal adenoma risk is modified by the interplay between polymorphisms in arachidonic acid pathway genes and fish consumption. Carcinogenesis 2005; 26: 449-57.
26. Yu KD, Chen AX, Yang C, et al. Current evidence on the relationship between polymorphisms in the COX-2 gene and breast cancer risk: a meta-analysis. Breast Cancer Res Treat 2010; 122: 251-7.
27. Schonfeld SJ, Bhatti P, Brown EE, et al. Polymorphisms in oxidative stress and inflammation pathway genes, low-dose ionizing radiation, and the risk of breast cancer among US radiologic technologists. Cancer Causes Control 2010; 21: 1857-66.
28. Simonsson M, Soderlind V, Henningson M, et al. Coffee prevents early events in tamoxifen-treated breast cancer patients and modulates hormone receptor status. Cancer Causes Control 2013; 24: 929-40.
29. Ringberg A, Bågeman E, Rose C, et al. Of cup and bra size: reply to a prospective study of breast size and premenopausal breast cancer incidence. Int J Cancer 2006; 119: 2242-3; author reply 4.
30. WHO. Physical status: the use and interpretation of anthropometry. Report of a WHO Expert Committee. World Health Organ Tech Rep Ser 1995; 854: 1-452.
31. Saunders JB, Aasland OG, Babor TF, et al. Development of the Alcohol Use Disorders Identification Test (AUDIT): WHO Collaborative Project on Early Detection of Persons with Harmful Alcohol Consumption-II. Addiction 1993; 88: 791-804.
32. Markkula A, Bromee A, Henningson M, et al. Given breast cancer, does breast size matter? Data from a prospective breast cancer cohort. Cancer Causes Control 2012; 23: 1307-16.
33. Markkula A, Hietala M, Henningson M, et al. Clinical profiles predict early nonadherence to adjuvant endocrine treatment in a prospective breast cancer cohort. Cancer Prev Res (Phila) 2012; 5: 735-45.
34. Jernström H, Bågeman E, Rose C, et al. CYP2C8 and CYP2C9 polymorphisms in relation to tumour characteristics and early breast cancer related events among 652 breast cancer patients. Br J Cancer 2009; 101: 1817-23.
35. Bågeman E, Ingvar C, Rose C, et al. Coffee consumption and CYP1A2*1F genotype modify age at breast cancer diagnosis and estrogen receptor status. Cancer Epidemiol Biomarkers Prev 2008; 17: 895-901.
36. Dupont W.D., Plummer W.D., PS: Power and Sample Size Calculation version 3.0, 2009 Department of Biostatistics, Vanderbilt University 2009. http://biostat.mc.vanderbilt.edu/wiki/Main/PowerSampleSize.
37. Altman DG, McShane LM, Sauerbrei W, et al. Reporting Recommendations for Tumor Marker Prognostic Studies (REMARK): explanation and elaboration. PLoS Med 2012; 9: e1001216.
38. Prueitt RL, Boersma BJ, Howe TM, et al. Inflammation and IGF-I activate the Akt pathway in breast cancer. Int J Cancer 2007; 120: 796-805.
39. Hannan EL,. Randomized clinical trials and observational studies: guidelines for assessing respective strengths and limitations. JACC Cardiovasc Interv 2008; 1: 211-7.
40. Platet N, Cathiard AM, Gleizes M, et al. Estrogens and their receptors in breast cancer progression: a dual role in cancer proliferation and invasion. Crit Rev Oncol Hematol 2004; 51: 55-67.
41. Jernström H, Sandberg T, Bågeman E, et al. Insulin-like growth factor-1 (IGF1) genotype predicts breast volume after pregnancy and hormonal contraception and is associated with circulating IGF-1 levels: implications for risk of early-onset breast cancer in young women from hereditary breast cancer families. Br J Cancer 2005; 92: 857-66.
42. Hartmann BW, Laml T, Kirchengast S, et al. Hormonal breast augmentation: prognostic relevance of insulin-like growth factor-I. Gynecol Endocrinol 1998; 12: 123-7.
43. Periyasamy-Thandavan S, Takhar S, Singer A, et al. Insulin-like growth factor 1 attenuates antiestrogen- and antiprogestin-induced apoptosis in ER+ breast cancer cells by MEK1 regulation of the BH3-only pro-apoptotic protein Bim. Breast Cancer Res 2012; 14: R52.
44. Zhang Y, Moerkens M, Ramaiahgari S, et al. Elevated insulin-like growth factor 1 receptor signaling induces antiestrogen resistance through the MAPK/ERK and PI3K/Akt signaling routes. Breast Cancer Res 2011; 13: R52.
45. Chiu SY, Duffy S, Yen AM, et al. Effect of baseline breast density on breast cancer incidence, stage, mortality, and screening parameters:25-year follow-up of a Swedish mammographic screening. Cancer Epidemiol Biomarkers Prev 2010; 19: 1219-28.
46. Ozhan G, Lochan R, Leathart JB, et al. Cyclooxygenase-2 polymorphisms and pancreatic cancer susceptibility. Pancreas 2011; 40: 1289-94.
47. Thang VH, Tani E, Johansson H, et al. Difference in hormone receptor content in breast cancers from Vietnamese and Swedish women. Acta Oncol 2011; 50: 353-9.
48. Zhang S, Ivy JS, Diehl KM, et al. The association of breast density with breast cancer mortality in African American and white women screened in community practice. Breast Cancer Res Treat 2013; 137: 273-83.
49. Sung J, Song YM, Stone J, et al. Association of body size measurements and mammographic density in Korean women: the Healthy Twin study. Cancer Epidemiol Biomarkers Prev 2010; 19: 1523-31.
50. Ray JG, Mohllajee AP, van Dam RM, et al. Breast size and risk of type 2 diabetes mellitus. CMAJ 2008; 178: 289-95.